Other Events ·
Eton Pharmaceuticals launches IMPAVIDO capsules for leishmaniasis with $0 co-pay program
ETONEton Pharmaceuticals, Inc.
On September 28, 2026, Eton Pharmaceuticals announced the U.S. commercial launch of IMPAVIDO (miltefosine) capsules, securing exclusive commercialization rights for the antileishmanial drug. The company integrated full Eton Cares patient support services, including a $0 co-pay program for eligible commercially insured patients and expanded assistance programs. Distribution is managed through Anovo Specialty Pharmacy to facilitate outpatient prescribing, inpatient consignment, and urgent access coordination. This launch expands Eton's portfolio of rare disease treatments within its existing commercial infrastructure.